Alaunos Therapeutics (NASDAQ:TCRT) Stock Breaks Below Fifty Day Moving Average – Should You Sell?

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) passed below its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $1.64 and traded as low as $1.60. Alaunos Therapeutics shares last traded at $1.61, with a volume of 93,807 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 17th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, Alaunos Therapeutics presently has an average rating of “Sell”.

Alaunos Therapeutics Stock Down 5.8%

The stock has a market capitalization of $5.33 million, a PE ratio of -0.84 and a beta of -1.02. The company has a 50-day moving average of $1.64 and a 200 day moving average of $2.29.

Alaunos Therapeutics (NASDAQ:TCRT) last issued its earnings results on Friday, August 14th. The company reported ($0.41) earnings per share for the quarter.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc. is a biotechnology company focused on developing genetically engineered T-cell therapies for cancer. The company has concentrated on T-cell receptor (TCR) therapies designed to recognize and attack tumor-specific mutations, with an emphasis on treating solid tumors that can be difficult to address with conventional immunotherapies. The company’s research platform has included the Sleeping Beauty gene-transfer system, a nonviral technology intended to introduce therapeutic T-cell receptors into a patient’s own T cells.